InMed Pharmaceuticals Inc (INM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InMed Pharmaceuticals Inc (INM) has a cash flow conversion efficiency ratio of -6.543x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.03 Billion) by net assets ($1.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of InMed Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
InMed Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2001–2026)
This chart illustrates how InMed Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
InMed Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InMed Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore INM operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cooper Metals Ltd
AU:CPM
|
-0.020x |
|
Pacific Empire Minerals Corp
F:1YK
|
-0.237x |
|
REFINED METALS CORP. O.N.
F:CWA0
|
-0.684x |
|
Seafarms Group Ltd
AU:SFG
|
2.045x |
|
IL&FS Transportation Networks Limited
NSE:IL&FSTRANS
|
0.000x |
|
PLAYWITH Inc
KQ:023770
|
-0.027x |
|
Safello Group AB
ST:SFL
|
-0.236x |
|
Metro Realty Tbk
JK:MTSM
|
-0.091x |
Annual Cash Flow Conversion Efficiency for InMed Pharmaceuticals Inc (2001–2026)
The table below shows the annual cash flow conversion efficiency of InMed Pharmaceuticals Inc from 2001 to 2026. View INM share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $1.08 Billion | $-8.64 Billion | -8.040x | -1794.80% |
| 2025-06-30 | $18.30 Million | $-7.77 Million | -0.424x | +23.52% |
| 2024-06-30 | $12.59 Million | $-6.99 Million | -0.555x | -22.01% |
| 2023-06-30 | $16.02 Million | $-7.28 Million | -0.455x | +65.89% |
| 2022-06-30 | $11.69 Million | $-15.58 Million | -1.333x | -24.22% |
| 2021-06-30 | $9.12 Million | $-9.79 Million | -1.073x | +14.46% |
| 2020-06-30 | $5.88 Million | $-7.37 Million | -1.255x | -98.63% |
| 2019-06-30 | $13.88 Million | $-8.77 Million | -0.632x | -254.14% |
| 2018-06-30 | $20.62 Million | $-3.68 Million | -0.178x | +53.82% |
| 2017-06-30 | $6.13 Million | $-2.37 Million | -0.386x | +17.93% |
| 2016-06-30 | $820.48K | $-386.07K | -0.471x | +62.66% |
| 2015-06-30 | $1.28 Million | $-1.61 Million | -1.260x | -198.64% |
| 2014-06-30 | $1.52 Million | $-641.38K | -0.422x | -147.41% |
| 2013-06-30 | $-44.11K | $-39.26K | 0.890x | +101.38% |
| 2012-06-30 | $2.72K | $-174.62K | -64.269x | -2213.15% |
| 2011-06-30 | $202.29K | $-562.05K | -2.778x | -1806.55% |
| 2010-06-30 | $-1.20 Million | $-195.42K | 0.163x | +266.73% |
| 2009-06-30 | $-1.03 Million | $100.48K | -0.098x | -101.43% |
| 2008-06-30 | $-138.98K | $-951.15K | 6.844x | +366.18% |
| 2007-06-30 | $-950.42K | $-1.40 Million | 1.468x | +23.41% |
| 2006-06-30 | $-485.38K | $-577.40K | 1.190x | +13.61% |
| 2005-06-30 | $-670.63K | $-702.23K | 1.047x | -49.06% |
| 2004-06-30 | $-235.55K | $-484.19K | 2.056x | +158.86% |
| 2003-06-30 | $241.85K | $-844.62K | -3.492x | -293.57% |
| 2002-06-30 | $1.29 Million | $-1.14 Million | -0.887x | -686.17% |
| 2001-06-30 | $4.18 Million | $-471.69K | -0.113x | -- |
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufactur… Read more